A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Investigational varicella vaccine of Lot 1 administered subcutaneously.

Investigational varicella vaccine of Lot 2 administered subcutaneously.

Investigational varicella vaccine of Lot 3 administered subcutaneously.

Marketed varicella vaccine of Lot 1 administered subcutaneously.

Marketed varicella vaccine of Lot 2 administered subcutaneously.

MMR vaccine co-administered subcutaneously or intramuscularly.

Hepatitis A vaccine co-administered intramuscularly.

The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.